As we now show that BET inhibitors decrease PD-L1 expression, and since BET inhibitors can enhance response to anti-PD-1 antibody in MYC-expressing lymphoma tumors15, it is possible that BET inhibitors may also enhance response to immune checkpoint inhibitors in pancreatic cancer. This evidence concerns the gene MYC and familial pancreatic carcinoma.